drug · antibody
tildrakizumab
pre_registrationupdated 3mo agoby Sun Pharmaceutical Industries Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 1Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Interleukin-23
all catalysts(0)
nothing on the calendar yet
Trials studying tildrakizumab
- phase3A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
- phase3Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
- phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
- —Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
- —Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
- —A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
- —Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
- —A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
News(1)
- Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pillSet to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.biopharma_dive · 1mo ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that